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Chemotherapy treatments induce a number of side effects, such as leukopenia neutropenia, peripheral erythropenia, and
thrombocytopenia, affecting the quality of life for cancer patients. 5-Fluorouracil (5-FU) is wieldy used as myeloablative model in
mice. The bovine dialyzable leukocyte extract (bDLE) or IMMUNEPOTENT CRP (ICRP) is an immunomodulatory compound
that has antioxidants and anti-inflammatory effects. In order to investigate the chemoprotection effect of ICRPon bonemarrow cells
in 5-FU treatedmice, total bonemarrow (BM) cell count, bonemarrow colony forming units-granulocyte/macrophage (CFU-GM),
cell cycle, immunophenotypification, ROS/superoxide and Nrf2 by flow cytometry, and histological and hematological analyses
were performed. Our results demonstrated that ICRP increased BM cell count and CFU-GM number, arrested BM cells in G0/G1
phase, increased the percentage of leukocyte, granulocytic, and erythroid populations, reduced ROS/superoxide formation and
Nrf2 activation, and also improved hematological levels and weight gain in 5-FU treated mice. These results suggest that ICRP has
a chemoprotective effect against 5-FU in BM cells that can be used in cancer patients.
1. Introduction
Most of chemotherapeutic agents can cause myelosuppres-
sion in a dose-dependent manner [1]. Other side effects of
chemotherapy are alopecia, stomatitis, immunosuppression,
anorexia, nausea, and vomiting which result in a decreased
functional capacity and quality of life for cancer patients [2].
5-Fluorouracil (5-FU) is a chemotherapeutic agent used to
treat gastrointestinal, breast, pancreatic, and head and neck
cancer, among others [3]. The mechanism of cytotoxicity
of 5-FU has been ascribed to the misincorporation of fluo-
ronucleotides into RNA and DNA and to the inhibition of
the nucleotide synthetic enzyme thymidylate synthase [4].
5-FU distributes readily into bone marrow, small intestine,
kidney, liver, and spleen [5, 6]. In the bone marrow 5-
FU, it is incorporated in the DNA and induces oxidative
stress, which is partly responsible for myelotoxicity [7, 8].
It is well known that patients treated with 5-FU are cursed
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with neutropenia, mucositis, leukopenia, and hematological
toxicity [9, 10]. Because of these side effects, chemoprotective
compounds have been used to reduce these problems [11–19].
Bovine dialyzable leukocyte extract or IMMUNEPOTENT
CRP (ICRP) is a dialysate of a heterogeneous mixture of
low-molecular-weight substances released fromdisintegrated
leukocytes of the blood or lymphoid tissue obtained from
homogenized bovine spleen. ICRPwas capable of stimulating
the immune system in patients with non-small cell lung
cancer and increasing their quality of life [20]. Also, in vitro
studies demonstrated that ICRP was an effective therapeutic
agent in process involving oxidative cellular damage and
clinical inflammatory diseases, through I𝜅B/NF-𝜅B pathway
[21]. In this study, we examined the protector effect of ICRP
on myelosuppression caused by 5-FU in a mouse model.
2. Materials and Methods
2.1. Animals. Nine-week-oldmale Balb/cmice were obtained
from the bioterium of the Laboratorio de Inmunologı´a y
Virologı´a de la Facultad de Ciencias Biolo´gicas. The mice
were maintained on pelleted food and water ad libitum
and housed in controlled environmental conditions (25∘C
and a 12 h light/dark cycle). The protocol for the animal
study was approved by Ethic Review Committee for Animal
Experimentation of the Facultad de Ciencias Biolo´gicas,
UANL.
2.2. Reagents. 5-Fluorouracil (5-FU) (Flurox) was purchased
fromLemery (Mexico). N-Acetylcysteine (NAC)was obtained
from Sandoz Pharmaceuticals (Mexico). IMMUNEPOTENT
CRP (ICRP) was produced by the Laboratorio de Inmu-
nologı´a y Virologı´a, Facultad de Ciencias Biolo´gicas, UANL
(San Nicola´s de los Garza, Nuevo Leo´n, Mexico). ICRP is
a low-molecular-weight product (10–12 kDa) from bovine
spleen. The extract is dialyzed, lyophilized, and determined
as pyrogen-free by Limulus of amoebocyte lysate assay (Endo-
toxin detection kit, ICN Biomedical, Aurora, OH, USA). The
ICRP obtained from 1 × 108 leukocytes is defined as one unit
(1 U).
2.3. Experimental Design. Mice were randomly divided into
5 groups as follows:
Control: injected i.p. on day 0 and i.m. for 6 consecu-
tive days with the vehicle (deionized water).
5-FU: injected i.p. with 5-FU in a single dose of
75mg/kg.
NAC+ 5-FU: injected i.p.withNAC in a single dose of
250mg/kg and one hour later with 5-FU i.p. in a single
dose of 75mg/kg as a positive protection control [7].
ICRP: injected i.m. with ICRP (5U) for 6 consecutive
days.
ICRP + 5-FU: injected i.m.with ICRP (5U), one hour
later with 5-FU i.p. in a single dose of 75mg/kg, and
for the 6 consecutive days with ICRP (5U) per day.
The animals were sacrificed on day 1 and day 7 to perform the
experiments.
2.4. Preparation of Bone Marrow (BM) Cell Suspension.
After the mice were sacrificed, both femurs and tibias were
dissected. Bone marrow cells were flushed with 5mL of
Iscove’s Modified Dulbecco’s Medium (IMDM) and supple-
mented with 2% fetal bovine serum (FBS), antimitotic, and
antibiotics. Cells suspensions were centrifuged at 1600 rpm
for 10min and washed twice in IMDM. Final suspension
was used for total bone marrow cell count, bone marrow
colony forming units-granulocyte/macrophage (CFU-GM)
assay, cell cycle, and flow cytometric analysis.
2.5. Total BM Cell Count. After the cells were pooled from
both femurs and tibias, a count was done by trypan blue
exclusion technique, which helps us exclude dead cells from
viable cells. To calculate the number of cells obtained from
each mouse, 50 𝜇L of the cell suspension was taken and
this was transferred to 400 𝜇L of medium plus 50𝜇L of
trypan blue; 10 𝜇L of this suspension was taken and placed
in the Neubauer chamber (Bright Line, Reichert, USA).
Observation was performed under a microscope at 10x and
viable cells present were counted.
2.6. CFU-GM Assay. A total of 1 × 106 BM cells were
resuspended in 1mL IMDM supplemented with 2% of FBS,
and then 300𝜇L of this suspension was added to 3mL of
mousemethylcellulose complete media (R&D Systems). Sub-
sequently, the mixture was collected with a 3mL syringe and
1.1mL of the final mixture was placed in a 35mm diameter
culture dish; this was done in duplicate. The incubation
of dishes was performed according to the manufacturer’s
instructions. The formation of colonies was observed by
microscopy, and the total number of colonies in each dishwas
counted.
2.7. Cell Cycle Analysis. The staining procedures were per-
formed using a BD Cycle Test Plus DNA Reagent Kit accord-
ing to the instructions of the manufacturer. Cell cycle phase
distributions were analyzed in Accuri C6 flow cytometer (BD
Biosciences, San Jose, CA). In addition, the percentage of cells
in each phase of cell cycle was analyzed by FlowJo software
(Treestar, Inc., San Carlos, CA).
2.8. Flow Cytometric Analysis. For immunophenotyping,
BM cells were stained using fluorescent label-conjugated
anti-CD71, anti-ter119, anti-CD45, anti-CD11b, and anti-Gr-1
antibodies (BD Biosciences, San Jose, CA). For intracellular
staining, NRF2 (D1Z9C) XP Rabbit mAb (PE Conjugate)
was used, following the technique provided by the manufac-
turer. For measure of oxidative stress, Total ROS/Superoxide
detection kit was used (Enzo Life Sciences). The stained cells
were analyzed by Accuri C6 flow cytometer and CFlow plus
software (BD Biosciences, San Jose, CA).
2.9. Histopathological Analysis. The left femoral bone of each
mouse was prepared for general histopathological evalua-
tion, including fixation, decalcification, and sectioning (4 𝜇m
thickness), as well as hematoxylin and eosin (HE) staining.
Histopathological analysis was done by a veterinarian pathol-
ogist.
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Figure 1: Total bone marrow cell count: BM cells from both femurs
and tibias were obtained on day 1 and day 7 from treated mice.
Subsequently, BM cells were counted by trypan blue dye exclusion
∗
(𝑃 < 0.05) (𝑛 = 3).
2.10. Hematological Analysis. Blood collection was done by
cardiac puncture in EDTA containing vials for immediate
analysis of hematological parameters. Hematological analysis
was determined by standard clinical procedures using an
automatic hematological analyzer (COULTER Ac⋅T diff
Analyzer, Beckman Coulter).
2.11. Weight Gain. Measurement of weight in grams of the
mice was performed at the beginning of treatment and seven
days later. Weight gain was calculated by subtracting the final
weight minus initial weight.
2.12. Statistical Analysis. Data was presented as mean ±
SD and statistically analyzed using one-way ANOVA test
followed by Tukey multiple comparison posttest at 𝑃 < 0.05
(𝑛 = 3) using SPSS v17 software.
3. Results
3.1. ICRP Restores the Number and Function of BM Cells in 5-
FU Treated Mice. The evaluation of the total number of BM
cells and the number of CFU-GM was performed 1 and 7
days after the initiating treatment. The number of total BM
cells was significantly (𝑃 < 0.05) decreased in all the groups
treated with 5-FU at day 1. Seven days later, the ICRP + 5-
FU group showed a recovery compared to 5-FU (𝑃 < 0.05)
and NAC + 5-FU groups. On the other hand, the use of ICRP
treatment by itself did not change, compared to the control
(Figure 1).
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Figure 2: Colony forming units-granulocyte/macrophage (CFU-
GM) assay: BM cells from both femurs and tibias were obtained
on day 1 and day 7 from treated mice. Subsequently, BM cells
were grown mouse methylcellulose complete media in a 5% CO
2
incubator for 14 days and colonies were counted ∗(𝑃 < 0.05) (𝑛 = 3).
When the evaluation of the number of CFU-GM was
done, we observed that ICRP and NAC treatments reversed
the side effects of 5-FU related to a decrease in the number
of CFU-GM colonies (𝑃 < 0.05) on day 1; seven days later,
NAC + 5-FU and ICRP + 5-FU groups increased the number
of CFU-GM compared to the control (Figure 2).
3.2. ICRP Does Not Affect Cell Cycle Phases on BM Cells
in 5-FU Treated Mice. Treatment with 5-FU significantly
decreased S phase and NAC and ICRP treatments did not
change this effect on BM cells. The 5-FU group increased
the percentage of Sub-G1 phase, which indicates that cells
are under apoptosis, on day 1. The cell cycle was not affected
(𝑃 < 0.05) by treatments on day 7 (Table 1).
3.3. ICRP Restores Leukocyte, Granulocyte, and Erythrocyte
Populations in BM Cells of 5-FU Treated Mice. To elucidate
the specific population that is protected by the ICRP, the
percentages of leukocyte (CD45+), granulocytic (CD11b+Gr-
1+), and erythroid (CD71, Ter119) lineages in BM cells were
evaluated by flow cytometry. On day one, leukocyte and
granulocytic populations were decreased (𝑃 < 0.05) by 5-
FU treatment; NAC and ICRP did not protect BM cells of
5-FU treated mice. The 5-FU group evaluated on day 7 kept
low percentages of CD45+ and CD11b+Gr-1+ populations but
ICRP + 5-FU group increased these populations (𝑃 < 0.05)
similar to the control group (Figure 3).
The protective effect of ICRP on erythroid lineage was
evident on days 1 and 7, because ICRP + 5-FU group
preserves highest percentages in basophilic erythroblast and
orthochromatic erythroblast stages of erythroid maturation
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Table 1: Effects of 5-FU, NAC + 5-FU, ICRP, and ICRP + 5-FU treatments on cell cycle phases in mice.
Cell cycle phases%
Groups G0/G1 S G2/M Sub-G1
Day 1
Control 71.97 ± 2.80 21.27 ± 1.93 4.32 ± 0.77 2.00 ± 0.27
5-FU 85.13 ± 3.25a 7.92 ± 1.03a 3.21 ± 1.06 4.10 ± 1.34a
NAC + 5-FU 86.10 ± 1.93a 7.40 ± 0.15a 3.18 ± 0.52 3.67 ± 0.57
ICRP 71.33 ± 2.26b,c 21.67 ± 1.46b,c 4.17 ± 1.31 3.20 ± 0.30
ICRP + 5-FU 89.53 ± 0.31a,d 6.15 ± 0.75a,d 2.86 ± 0.89 3.19 ± 0.99
Day 7
Control 79.27 ± 1.95 15.87 ± 1.80 4.94 ± 1.21 2.51 ± 1.09
5-FU 66.57 ± 11.05 22.47 ± 6.76 5.82 ± 1.57 7.37 ± 3.48
NAC + 5-FU 70.30 ± 0.95 25.03 ± 0.70 6.56 ± 2.53 2.12 ± 0.73
ICRP 73.80 ± 7.71 18.27 ± 3.95 8.17 ± 4.09 4.69 ± 1.65
ICRP + 5-FU 67.40 ± 2.72 21.70 ± 4.52 8.34 ± 5.52 5.12 ± 3.63
Data are expressed as mean ± SD (𝑃 < 0.05) (𝑛 = 3).
a: significantly different from the control group.
b: significantly different from 5-FU group.
c: significantly different from NAC + 5-FU group.
d: significantly different from ICRP group.
Table 2: Effects of 5-FU, NAC + 5-FU, ICRP, and ICRP + 5-FU on erythrocyte population in treated mice.
Erythrocyte population%
Groups IProerythroblasts
II
Basophilic erythroblasts
III
Orthochromatic
erythroblast
IV
Enucleated red blood
cells
Day 1
Control 0.53 ± 0.06 49.00 ± 2.65 6.60 ± 0.46 25.17 ± 1.07
5-FU 0.07 ± 0.12a 40.07 ± 4.56a 3.50 ± 0.20a 31.03 ± 2.57a
NAC + 5-FU 0.23 ± 0.06 39.67 ± 3.28a 5.50 ± 0.30a,b 26.93 ± 2.93
ICRP 0.30 ± 0.00b 51.80 ± 0.36b,c 6.50 ± 0.30b,c 20.53 ± 0.45b,c
ICRP + 5-FU 0.20 ± 0.10 57.03 ± 2.59b,c 4.20 ± 0.26a,c,d 20.20 ± 1.55a,b,c
Day 7
Control 0.33 ± 0.05 48.3 ± 1.95 3.10 ± 0.87 20.57 ± 2.48
5-FU 0.27 ± 0.11 1.70 ± 0.26a 3.50 ± 0.88 71.87 ± 4.48a
NAC + 5-FU 4.40 ± 2.40a,b 27.3 ± 5.66b 6.67 ± 1.52a,b 21.63 ± 3.3b
ICRP 0.63 ± 0.05c 51.9 ± 3.93b,c 4.90 ± 0.40 20.77 ± 4.31b
ICRP + 5-FU 4.13 ± 0.77a,b,d 52.1 ± .59b,c 6.83 ± 0.70a,b 16.30 ± 1.57b
Data are expressed as mean ± SD (𝑃 < 0.05) (𝑛 = 3).
a: significantly different from the control group.
b: significantly different from 5-FU group.
c: significantly different from NAC + 5-FU group.
d: significantly different from ICRP group.
Populations I to IV represent progressive maturation of erythroid cells. Populations are characterized by I, proerythroblasts; II, basophilic erythroblasts; III,
orthochromatic erythroblast; and IV, enucleated red blood cells.
compared with 5-FU group (𝑃 < 0.05). Enucleated red blood
cells were the predominant population in 5-FU treated mice;
these findings are different to the control and ICRP + 5-FU
groups (Figure 4 and Table 2).
3.4. ICRP Decreased ROS/Superoxide Formation and Nrf2
Activation Induced by 5-FU. The ROS/superoxide formation
and Nrf2 activation were induced on day 1 and day 7 by 5-
FU treatment and the ICRP + 5-FU treatment decreases these
parameters on day 7; no statistical difference was found on
day 1 (Figure 5).
3.5. Histopathologic Analysis. The effect of ICRP on the
histopathology of bone marrow at 1 and 7 days is shown
in Figure 6 and described at continuation; 5-FU treatment
decreased the cell density of bonemarrow, creating a hypocel-
lular environment, with marked decrease of megakaryocytes
and granulocytic lineage cells, and no large amount of
Journal of Immunology Research 5
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Figure 3: Continued.
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Figure 3: Flow cytometry analysis: BM cells from both femora and tibia were obtained on day 7 from treated mice. Subsequently, BM cells
were analyzed for expression of the cell surface markers by flow cytometry. (a) Representative result of flow cytometry analysis for CD45+ BM
cells. (b) Statistics from CD45+ BM cells. (c) Representative result of flow cytometry analysis for CD11b+Gr-1+ BM cells. (d) Statistics from
CD11b+Gr-1+ BM ∗(𝑃 < 0.05) (𝑛 = 3).
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Figure 4: Flow cytometry analysis: representative result of flow cytometry analysis. BM cells from both femurs and tibias were obtained on
day 7 from treated mice. Subsequently, BM cells were analyzed for expression of the cell surface markers CD71 and Ter119 by flow cytometry.
Populations I to IV represent progressive maturation of erythroid cells. Populations are characterized by I, proerythroblasts; II, basophilic
erythroblasts; III, orthochromatic erythroblast; and IV, enucleated red blood cells.
precursor cells was found. NAC and ICRP treatments protect
bone marrow because they present a higher proportion in
differentiated precursor cells and cellularity. The ICRP group
showed normal myeloid tissue cellularity.
3.6. Effects of ICRP on Hematotoxicity and Gain of Body
Weight in 5-FU Treated Mice. We examined the effects
of ICRP on 5-FU treated mice on red blood cell (RBC),
hemoglobin (HB), hematocrit (HCT), white blood cell
(WBC), and platelets (PLT) levels 1 and 7 days after initiating
treatments. The 5-FU group resulted in anemia and erythro-
cytopenia and decreased the hematocrit level on day 1 and
day 7. The leucopenia was observed only in day 1. The ICRP
+ 5-FU group did not present any of these toxic effects; their
values were similar to the control group (Table 3). The 5-FU
treated mice gained less body weight (𝑃 < 0.05) compared to
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Figure 5: (a) ROS/superoxide analysis: BM cells fromboth femora and tibia were obtained on day 1 and day 7 from treatedmice. Subsequently,
BM cells were stained for ROS/superoxide detection by flow cytometry. (b) Nrf2 analysis: BM cells from both femora and tibia were obtained
on day 1 and day 7 from treated mice. Subsequently, BM cells were fixed and permeabilized for intracellular staining ∗(𝑃 < 0.05) (𝑛 = 3).
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Figure 6: Bone marrow histology: on day 1 and day 7, femora of treated mice were harvested, fixed, sectioned, and stained with hematoxylin
and eosin. The histological description was made by a pathologist; photographs were taken under a microscope at 40x.
the control. The ICRP + 5-FU group increased body weight
similar to the control group (Table 4).
4. Discussion
The chemotherapy with 5-FU is widely used since its discov-
ery to treat a variety of tumors, including colorectal, breast,
and liver carcinomas [22]. The hematologic toxicity induced
by chemotherapy is related to the dose-limiting side effect,
affecting the therapeutic success and quality of life of patients
[23]. The 5-FU as a model of bone marrow depletion has
been used by many researchers [7, 13, 16, 17, 24–28]; in the
present study, we corroborated that a single dose of 5-FU
8 Journal of Immunology Research
Table 3: Effects of 5-FU, NAC + 5-FU, ICRP, and ICRP + 5-FU on peripheral blood analysis in treated mice.
Peripheral blood analysis
Group RBC count × 106 HB level g/dL HCT level (%) WBC mm3 PLT mm3
Day 1
Control 8.00 ± 0.35 12.50 ± 0.85 36 ± 4 4.67 ± 0.49 534.33 ± 170.28
5-FU 4.43 ± 0.31a 6.87 ± 0.61a 20 ± 2a 1.50 ± 0.44a 318.33 ± 123.31
NAC + 5-FU 6.97 ± 0.81b 11.30 ± 1.39b 32 ± 5b 2.23 ± 0.85 393.00 ± 54.29
ICRP 8.30 ± 0.44b 13.10 ± 0.72b 39 ± 2b 6.37 ± 1.77b,c 448.67 ± 108.84
ICRP + 5-FU 6.90 ± 1.14b 11.03 ± 1.61b 32 ± 5b 4.13 ± 0.91 472.33 ± 159.53
Day 7
Control 7.60 ± 0.92 11.63 ± 1.65 34 ± 6 5.03 ± 0.95 525.00 ± 184.01
5-FU 4.83 ± 1.27a 7.73 ± 2.48a 22 ± 7 3.13 ± 1.90 260.67 ± 122.92
NAC + 5-FU 6.93 ± 0.59b 10.50 ± 0.95 32 ± 3 5.60 ± 3.74 380.00 ± 34.18
ICRP 8.63 ± 0.15b 13.43 ± 0.50b 42 ± 5b 6.27 ± 1.87 470.67 ± 82.78
ICRP + 5-FU 7.73 ± 0.35b 12.17 ± 0.45b 36 ± 2b 4.57 ± 1.10 600.00 ± 89.21b
Data are expressed as mean ± SD (𝑃 < 0.05) (𝑛 = 3).
a: significantly different from the control group.
b: significantly different from 5-FU group.
c: significantly different from NAC + 5-FU group.
Red blood cell (RBC), hemoglobin (HB), hematocrit (HCT), white blood cell (WBC), and platelets (PLT).
Table 4: Effects of 5-FU, NAC + 5-FU, ICRP, and ICRP + 5-FU on body weight gain in treated mice.
Body weight
Group Initial body weight (g) Final body weight (g) Body weight gain (g)
Control 26.50 ± 3.00 29.75 ± 2.63 3.25 ± 0.50
5-FU 24.00 ± 4.62 25.25 ± 4.35 1.25 ± 0.50a
NAC + 5-FU 23.50 ± 5.20 25.25 ± 5.06 1.75 ± 0.50a
ICRP 25.50 ± 4.51 29.00 ± 4.97 3.50 ± 0.58b,c
ICRP + 5-FU 25.75 ± 3.59 28.75 ± 4.03 3.00 ± 0.82b
Data are expressed as mean ± SD (𝑃 < 0.05) (𝑛 = 3).
a: significantly different from the control group.
b: significantly different from 5-FU group.
c: significantly different from NAC + 5-FU group.
(75mg/kg) reduces the number of CFU-GM [7], which indi-
cates that bonemarrow lineage commitment and proliferative
potential are affected [29].The ICRP treatment demonstrates
an efficient chemoprotection to 5-FU treatment, due to an
increase in bone marrow progenitor cells function, such as
those found with the use of amifostine, which is a clinical
radioprotector [30].
This effect on progenitor cells can be correlated with
the capacity of ICRP to protect more committed lineages in
bone marrow cells, such as leukocyte (CD45+), granulocyte
(CD11b+Gr-1+), and erythroid populations (CD71, Ter119)
which are affected by 5-FU [27, 31], and also with normal
hematological values of WBC and RBC in a systemic level.
Other studies have previously used animal models and
peripheral blood reconstitution as measure of bone marrow
recovery after chemotherapy [32, 33]. These results could be
used to reduce infections and anemia experienced by patients
receiving chemotherapy [34].
In this study, cell cycle analysis was used to determine
whether the observed chemoprotection is related to cell cycle
arrest at any phase. It is known that the mechanism of
cytotoxicity of 5-FU is on actively proliferating cells (S phase)
including healthy and cancer cells [35, 36]. Agents such as
tetrapeptide acetyl-N-Ser-Asp-Lys-Pro (AcSDKP) and TGF-
𝛽 can protect marrow progenitor cells due to the induction
of G0/G1 arrest, being an alternative to chemoprotection
therapy [37, 38]. In our study, ICRP and NAC did not
affect cell cycle in bone marrow cells, suggesting another
mechanism of action in the protection of 5-FU treated bone
marrow cells.
It is know that 5-FU induces oxidative stress in bone
marrow cells [7] and this leads to the activation of Nrf2
transcription factor [39, 40]; therefore, several researchers
explain the mechanism of chemoprotection of different com-
pounds for their ability to activate the antioxidant response
and neutralizing ROS [41]. Our results indicate that ICRP
decreased ROS/superoxide production and Nrf2 activation
in 5-FU treated bone marrow cells on 7 day; this could
be explained because ICRP has an antioxidant capacity by
increasing glutathione peroxidase, catalase, and superoxide
dismutase enzymes [21]; further studies are needed to clarify
whether these enzymes are responsible for decreasing ROS
production in bone marrow. These results would suggest
that ICRP might act as free radical scavenger, similar to
aminothiols and phosphorothioates, two protective agents
widely used [42].
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All these effects of chemoprotection are reflected in our
histopathology analysis; this kind of technique is used to
assess the bone marrow architecture, cellularity, estimation
of iron stores, and other features [43]. It is important that
patients receiving chemotherapy can maintain their weight
in order to improve health-related quality of life [44]; we
found that ICRP helps to maintain normal weight after 5-
FU treatment, which indicates that ICRP could improve the
quality of life in cancer patients. It is known thatNACprotects
the cytotoxic and apoptotic effects against cisplatin in human
tumor cell lines, because NAC blocks the death receptor and
mitochondrial apoptotic pathways [45].This is necessary in in
vitro and in vivo studies to determinate if ICRP has antagonist
action against tumor cells treated with chemotherapy due
to its antioxidant activity showed in this study. Current
studies about that are running in our laboratory. Although
in previous studies ICRP has been administrated to patients
with breast and lung cancer as an adjuvant to avoid secondary
effects in combinationwith chemotherapy, therewas no effect
on the tumor regression and improving the quality of life
[20, 46].
5. Conclusion
It is important to investigate new compounds that could
be given during chemotherapy treatment and help us to
alleviate some side effects, resulting in a significant increase
in chemotherapy doses. Our results suggest that the ICRP can
be proposed as a chemoprotective agent because it is able to
protect the damage caused by 5-FU in bone marrow cells,
ROS production, hematological parameters, and weight gain
probably by its antioxidant or immunomodulatory capacity.
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